Omnicell (NASDAQ:OMCL) was downgraded by equities researchers at BidaskClub from a “sell” rating to a “strong sell” rating in a report issued on Friday.

Other research analysts have also recently issued research reports about the company. Zacks Investment Research cut Omnicell from a “hold” rating to a “sell” rating in a research note on Wednesday, January 10th. Oppenheimer reissued a “buy” rating and issued a $55.00 price objective on shares of Omnicell in a research note on Tuesday, December 5th. Craig Hallum reissued a “buy” rating and issued a $62.00 price objective (up previously from $52.00) on shares of Omnicell in a research note on Monday, October 30th. Finally, Cantor Fitzgerald reissued a “buy” rating and issued a $60.00 price objective on shares of Omnicell in a research note on Tuesday, December 5th. Two analysts have rated the stock with a sell rating, two have issued a hold rating and six have assigned a buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus price target of $55.14.

Omnicell (OMCL) opened at $50.55 on Friday. Omnicell has a 52 week low of $32.70 and a 52 week high of $55.40. The stock has a market capitalization of $1,911.79, a P/E ratio of -459.55, a P/E/G ratio of 4.00 and a beta of 0.71. The company has a quick ratio of 1.08, a current ratio of 1.53 and a debt-to-equity ratio of 0.38.

Omnicell (NASDAQ:OMCL) last announced its quarterly earnings data on Thursday, October 26th. The company reported $0.42 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.42. Omnicell had a negative return on equity of 0.79% and a negative net margin of 0.51%. The company had revenue of $186.78 million for the quarter, compared to analysts’ expectations of $192.45 million. During the same quarter in the prior year, the firm earned $0.40 earnings per share. Omnicell’s revenue was up 5.7% compared to the same quarter last year. analysts expect that Omnicell will post 0.12 EPS for the current year.

In other Omnicell news, CFO Peter J. Kuipers sold 1,926 shares of the company’s stock in a transaction on Monday, December 18th. The stock was sold at an average price of $51.69, for a total transaction of $99,554.94. Following the completion of the sale, the chief financial officer now owns 40,544 shares in the company, valued at $2,095,719.36. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Also, VP Jorge R. Taborga sold 6,295 shares of the company’s stock in a transaction on Monday, November 6th. The stock was sold at an average price of $48.69, for a total value of $306,503.55. Following the sale, the vice president now owns 50,013 shares of the company’s stock, valued at approximately $2,435,132.97. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 27,558 shares of company stock valued at $1,330,230. 3.77% of the stock is owned by company insiders.

Institutional investors have recently bought and sold shares of the business. California Public Employees Retirement System lifted its holdings in Omnicell by 4.2% during the second quarter. California Public Employees Retirement System now owns 81,200 shares of the company’s stock worth $3,500,000 after buying an additional 3,300 shares during the period. Northern Trust Corp lifted its holdings in Omnicell by 6.0% during the second quarter. Northern Trust Corp now owns 515,757 shares of the company’s stock worth $22,230,000 after buying an additional 29,217 shares during the period. Kornitzer Capital Management Inc. KS lifted its holdings in Omnicell by 20.8% during the third quarter. Kornitzer Capital Management Inc. KS now owns 155,240 shares of the company’s stock worth $7,925,000 after buying an additional 26,700 shares during the period. Nationwide Fund Advisors lifted its holdings in Omnicell by 6.0% during the second quarter. Nationwide Fund Advisors now owns 269,177 shares of the company’s stock worth $11,602,000 after buying an additional 15,222 shares during the period. Finally, Parametric Portfolio Associates LLC lifted its holdings in Omnicell by 20.3% during the second quarter. Parametric Portfolio Associates LLC now owns 174,763 shares of the company’s stock worth $7,532,000 after buying an additional 29,484 shares during the period. Institutional investors own 99.61% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was published by Daily Political and is the sole property of of Daily Political. If you are viewing this piece on another domain, it was illegally copied and reposted in violation of United States & international copyright law. The legal version of this piece can be accessed at https://www.dailypolitical.com/2018/01/18/omnicell-omcl-downgraded-by-bidaskclub-to-strong-sell.html.

About Omnicell

Omnicell, Inc provides automation and business analytics software solutions for patient-centric medication and supply management across the entire healthcare continuum, from the acute care hospital setting to post-acute skilled nursing and long-term care facilities to the home. It operates through two segments: Automation and Analytics, and Medication Adherence.

Analyst Recommendations for Omnicell (NASDAQ:OMCL)

Receive News & Ratings for Omnicell Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Omnicell and related companies with MarketBeat.com's FREE daily email newsletter.